Ninlaro (ixazomib) / Takeda  >>  Phase 3
Welcome,         Profile    Billing    Logout  

11 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ninlaro (ixazomib) / Takeda
TOURMALINE-MM3, NCT02181413 / 2013-002076-41: A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Checkmark TOURMALINE-MM3 trial in post-SCT maintenance MM
Dec 2018 - Dec 2018: TOURMALINE-MM3 trial in post-SCT maintenance MM
Completed
3
656
Europe, Canada, Japan, US, RoW
Ixazomib Citrate, MLN9708, Placebo
Takeda
Multiple Myeloma, Autologous Stem Cell Transplant
04/18
09/23
ACTRN12616000772448: A Phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamethasone-Ixazomib consolidation for transplant eligible multiple myeloma patients undergoing a single autologous stem cell transplantation as part of front-line therapy

Active, not recruiting
3
310
 
Australasian Leukaemia and Lymphoma Group (ALLG), Takeda Pharmaceuticals U.S.A. Inc.
Multiple Myeloma
 
 
2021-001005-67: Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy Allogene Stammzelltransplantation im Vergleich zur konventionellen Therapie als Salvage-Therapie für Patienten mit rezidiviertem / progredientem Multiplem Myelom nach der Erstlinientherapie

Not yet recruiting
3
482
Europe
human allogeneic hematopoietic stem cells from peripheral blood stem cell collections, human autologous stem cells, DARZALEX® 20 mg/ml, Suspension for injection, Powder and solvent for concentrate for solution for infusion, Solution for injection, Capsule, hard, Concentrate and solvent for solution for infusion, , Powder for solution for injection, Powder for injection, Tablet, human allogeneic hematopoietic stem cells (allo-HSC) from peripheral blood stem cell (PBSC) collections, autologous stem cells, Kyprolis®, DARZALEX® 1 800 mg Injektionslösung, NINLARO®, Empliciti®, IMNOVID, DARZALEX® 20 mg/ml, REVLIMID® Hartkapseln, VELCADE 3,5 mg Pulver, Bortezomib medac 3,5 mg, Fortecortin® Inject, Fortecortin®
University Medical Center Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA)
Multiple myeloma, cancer that forms in a type of white blood cell called a plasma cell, Diseases [C] - Cancer [C04]
 
 
C16021 CCS, NCT03748953: Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

Completed
3
31
RoW
Ixazomib
Millennium Pharmaceuticals, Inc.
Multiple Myeloma
11/23
11/23
NCT03941860: Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

Active, not recruiting
3
1
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ixazomib Citrate, MLN 9708, MLN-9708, MLN9708, Ninlaro, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI)
Multiple Myeloma
08/23
04/25
NCT02516423: Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

Active, not recruiting
3
11
US
ixazomib, lenalidomide, dexamethasone, zoledronic acid
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc., Biologics, Inc.
Solitary Osseous Plasmacytoma
09/24
 
NCT04371770: Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

Active, not recruiting
3
105
RoW
Ixazomib, Ixazomib Placebo
Millennium Pharmaceuticals, Inc.
Multiple Myeloma
09/24
09/26
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
KarMMa-3, NCT03651128 / 2018-001023-38: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Oct 2022 - Dec 2023: Approval in US for 3-5L multiple myeloma
Hourglass Jun 2023 - Jun 2023 : Subgroup analysis of outcomes for patients with high-risk r/r multiple myeloma from the KarMMa-3 trial at EHA 2023
Checkmark Data from KarMMa-3 trial for 3L multiple myeloma
Aug 2022 - Aug 2022: Data from KarMMa-3 trial for 3L multiple myeloma
Active, not recruiting
3
381
Europe, Canada, Japan, US
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Celgene
Multiple Myeloma
04/27
04/27
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33

Download Options